Faron Pharmaceuticals researchers dose first patient in pivotal COVID-19 trial
The HIBISCUS study will be conducted across 10-15 sites in the US and will enrol 140 patients
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 9 of 21
Faron Pharmaceuticals’ bexmarilimab secures key US patent
The new patent covers the composition of matter of the cancer immunotherapy drug candidate and is expected to expire in 2037
Faron Pharmaceuticals flags up latest research assessing the potential of bexmarilimab in advanced cancer patients
The data, compiled by Dr Maija Hollmén and colleagues at the University of Turku, was published in the journal, Clinical Cancer Research
Faron Pharmaceuticals flags up latest research assessing the potential of bexmarilimab in advanced cancer patients
The data, compiled by Dr Maija Hollmén and colleagues at the University of Turku, was published in the journal, Clinical Cancer Research
Faron Pharmaceuticals reveals promising data from a clinical study of Bexmarilimab
"Bexmarilimab's ability to increase survival in patients who have exhausted all treatment options is significant," said Markku Jalkanen, Faron’s chief executive officer
Faron Pharmaceuticals in US sub-licence deal
It said the agreement clarifies its intellectual property position in the US
Faron Pharma making progress in finding potential partners for Clevegen and Traumakine
While discussions with potential partners proceed, the company has received substantial funding support from the market, putting it in a strong position to continue the progress of its pipeline
Faron Pharma says trial on precision cancer drug shows significant efficacy signals
The study's data monitoring committee has suggested investigating more frequent dosing schedules in patients showing early clinical benefit
Faron Pharma raises €15mln to 'expand and accelerate' work in the clinic
The European Investment Council Fund was the largest new investor
Faron Pharmaceuticals enjoys momentum as COVID-19 drug candidate gets green light for late-stage trials
Traumakine has also attracted the interest of the US Department of Defense, which was revealed to be a surprise backer
Faron Pharmaceuticals says US regulator gives phase II/III coronavirus trial the green light
Traumakine, an intravenous interferon beta-1a drug, will be given to people who have been hospitalised but who do not yet need ventilation
Archive
Proactive news headlines: Faron Pharmaceuticals, ANGLE, CMC Markets, Bango ...
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharmaceuticals says research suggests immune-stimulating effects of its drug may be broader than first thought
Faron has been working with Kaiku Health, a data science company that uses an artificial intelligence platform to analyse patient results following treatment with cancer immunotherapies
Faron Pharmaceuticals says US Department of Defense gets behind coronavirus study with US$6.1mln of funding
Faron will be working directly with the 59th Medical Wing of the US Air Force
Faron Pharmaceuticals: Scientists to showcase progress and scientific thinking in two presentations at leading cancer forum
Researchers have presentation slots at the European Society of Medical Oncology Immuno-Oncology Virtual Congress
Faron Pharma reports solid progress with phase I/II cancer trial; plans further studies
The company said it was seeing “exciting clinical activity across multiple cancer types” from bexmarilimab, formerly Clevegen
Faron Pharma says disappointed but not surprised by WHO coronavirus trial data
“They do support our long-held view that IFN beta-1a is likely to be ineffective when given subcutaneously."
Faron Pharma expects data from COVID-19 treatment trial in final quarter of 2020
Traumakine, an intravenously administered interferon beta -1a treatment, is part of the World Health Organisation’s global SOLIDARITY trial
Faron Pharma says scientist to discuss “promising” anti-tumour activity of phase I/II drug at leading cancer forum
Dr Petri Bono will take part in an on-demand segment at the European Society of Medical Oncology Virtual Congress
Faron Pharmaceuticals rises after Traumakine update
Faron is supporting global research efforts against coronavirus (COVID-19) and looks forward to receiving further data from clinical trials to support the potential use of Traumakine (IV IFN beta-1a)